# The efficacy of group hypnosis and relaxation in smoking cessation

Submission date	<b>Recruitment status</b> No longer recruiting	<ul><li>Prospectively registered</li></ul>		
15/08/2011		☐ Protocol		
Registration date 26/08/2011	Overall study status Completed	Statistical analysis plan		
		[X] Results		
Last Edited	Condition category	Individual participant data		
04/09/2014	Mental and Behavioural Disorders			

#### Plain English summary of protocol

Background and study aims

Scientists believe that hypnosis may help people stop smoking, but studies show unclear results. At the same time, people who want to give up smoking are not always able and willing to attend several sessions of therapy or to use medication. Therefore, we are investigating whether a single hypnosis session helps smokers quit smoking.

#### Who can participate?

You are invited to participate in the study if you are older than 18 years, if you smoke at least five cigarettes per day, if you want to quit and if you are not trying to give up smoking in any other way.

## What does the study involve?

You will attend a 40-minutes session of motivational training then you will be randomly allocated to attend a 40-minute group session of either hypnosis or relaxation. You will attend the session together with 10-15 other people. A trained hypnotherapist and relaxation instructor will lead the session.

What are the possible benefits and risks of participating?

There are no risks for you because hypnosis has hardly any side effects in healthy people. The results will provide information to tobacco prevention organisations in Switzerland on whether or not to recommend hypnosis as a method to stop smoking.

Where is the study run from?

Institut für Sucht- und Gesundheitsforschung (ISGF) (Switzerland).

When is the study starting and how long is it expected to run for? The study ran from April 2011 to June 2012.

Who is funding the study?
Tobacco Control Fund (Switzerland).

Who is the main contact?
Dr Michael Schaub
michael.schaub@isgf.uzh.ch

# **Contact information**

## Type(s)

Scientific

#### Contact name

Dr Michael Schaub

#### Contact details

Konradstrasse 32 Zurich Switzerland 8031 michael.schaub@isgf.uzh.ch

# Additional identifiers

**EudraCT/CTIS** number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

10.005768

# Study information

#### Scientific Title

Smoking cessation through group hypnosis: a randomised controlled trial

## Study objectives

A one-time session consisting of mental preparation followed by hypnosis or relaxation in a group setting helps smokers quit smoking. We hypothesise that 6 months following the intervention, at least 30% of participants in the hypnosis group and at least 18% of participants in the relaxation group will be abstinent.

## Ethics approval required

Old ethics approval format

#### Ethics approval(s)

Cantonal Ethical Committee of Zurich, 25/08/2010

#### Study design

Single-centre randomised controlled double-blind study with repeated measurements

#### Primary study design

Interventional

#### Secondary study design

Randomised controlled trial

#### Study setting(s)

GP practice

#### Study type(s)

Treatment

#### Participant information sheet

Patient information can be found at http://www.isgf.ch/index.php? id=94&no\_cache=1&tx\_ttnews[tt\_news]=27&tx\_ttnews[backPid] =9&cHash=859b89b6fa6ac5bd25fa181c4e58ae97%20 [German]

#### Health condition(s) or problem(s) studied

Public health, smoking, hypnosis, smoking cessation

#### **Interventions**

Two groups to be compared:

- 1. Participants receive 40 minutes of motivational training followed by 40 minutes of hypnosis in a group session (8 to 15 participants)
- 2. Participants receive 40 minutes of motivational training followed by 40 minutes of relaxation in a group session (8 to 15 participants)

Motivational training: the intention of the participants to quit smoking is reinforced in an oral presentation given by a trained instructor. The presentation focuses on participants life after smoking cessation.

Group hypnosis: deep relaxation is induced through repetitive statements and soft background music. During the hypnosis, suggestions reinforcing cigarette abstinence are made by a trained instructor.

Group relaxation: relaxation is induced through soft music. During the relaxation, suggestions reinforcing cigarette abstinence are made by a trained instructor.

All participants are contacted 2 weeks and 6 months following the intervention in order to check their smoking status, mental and physical health.

#### Intervention Type

Other

#### Phase

Not Applicable

#### Primary outcome measure

1. Number of participants smoking 2 weeks after each intervention (smoking defined as 5 or more cigarettes per day) (inter-subject design)

- 2. Number of participants smoking 6 months after each intervention (inter-subject design)
- 3. Changes in the number of daily cigarettes smoked from baseline to 2 weeks after the intervention (intra-subject design)
- 4. Changes in the number of daily cigarettes smoked from baseline to 6 months after the intervention (intra-subject design)
- 5. Changes in salivary cotinine levels from baseline to 6 months after the intervention (intrasubject design)

#### Secondary outcome measures

- 1. Depression (BDI-V, Schmitt et al. 2003; 2006) at baseline, 2 weeks and 6 months after the intervention
- 2. Anxiety (BAI, Beck et al. 1988, German version by Margraf & Ehlers) at baseline, 2 weeks and 6 months after the intervention
- 3. Expected self-efficacy in situations of high smoking temptation (Tönjes et al., 2007) at baseline and 2 weeks after the intervention
- 4. Adverse events (headache, insomnia, gastrointestinal problems etc.) 2 weeks and 6 months after the intervention

#### Overall study start date

20/04/2011

#### Completion date

01/06/2012

# **Eligibility**

#### Key inclusion criteria

- 1. Aged between 18 and 65 years
- 2. Smoking five or more cigarettes per day
- 3. Not taking any medication or following another program for smoking cessation
- 4. Willing to stop smoking
- 5. Not suffering from alcohol dependence or psychotic disorders
- 6. No intake of stimulating medication such as methylphenidate (Ritalin) or venlafaxine (Effexor®)

#### Participant type(s)

**Patient** 

#### Age group

Adult

#### Lower age limit

18 Years

#### Upper age limit

65 Years

#### Sex

Both

# Target number of participants

172

## Key exclusion criteria

Does not meet inclusion criteria

#### Date of first enrolment

20/04/2011

#### Date of final enrolment

01/06/2012

# Locations

#### Countries of recruitment

Switzerland

# Study participating centre

Konradstrasse 32

Zurich Switzerland 8031

# Sponsor information

# Organisation

Tobacco Control Fund (Switzerland)

#### Sponsor details

c/o Mr Peter Blatter Hessstrasse 27E Bern Switzerland 3003

#### Sponsor type

Government

#### **ROR**

https://ror.org/01qtc5416

# Funder(s)

## Funder type

Government

#### Funder Name

Tobacco Control Fund (Switzerland)

# **Results and Publications**

#### Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

# IPD sharing plan summary

Not provided at time of registration

## **Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	23/12/2013		Yes	No